BIOGEN INC. — Form 8-K
Filed July 29, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 56/100
What the filing says
Biogen reported Q2 2026 total revenue of $2.7 billion (+3% YoY). The Apellis acquisition closed May 14, 2026, adding SYFOVRE ($162M Q2 revenue) and EMPAVELI ($46M Q2 revenue). Growth Portfolio revenue reached $1.06 billion (+24% YoY). FY2026 Non-GAAP EPS guidance raised to $12.00–$13.00 (from $14.25–$15.25 in April), reflecting ~$0.85 dilution from Apellis deal financing and ~$2.00 IPR&D charges. Company expects $250M run-rate synergies exiting 2027 and Apellis accretion in 2027.
Why this rating
Apellis acquisition (~$8.1B debt incurred, material relative to $18.4B market cap) and guidance cut offset by strong underlying growth. Real but not trajectory-altering.
See more from July 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.